ArticleEJNMMI research2026
Biodistribution, dosimetry, and preliminary imaging of the novel Nectin-4-targeting PET tracer [⁶⁸Ga]Ga-FZ-NR-1 in humans.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual-Target Nectin-4/FAP Heterobivalent ProbeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNectin-4 is a promising theranostic target for cancers treatment due to its high abundance/expression in different cancer entities such as bladder cancer, breast cancer, and pancreatic cancer This study evaluated the biodistribution and radiation dosimetry of [⁶⁸Ga]Ga-DOTA-Sar¹⁰-Nectin-4 ([⁶⁸Ga]Ga-FZ-NR-1), a novel Nectin-4-targeting PET tracer developed by our team, to assess its safety and support its clinical translation. Eight patients with pathologically confirmed malignancies (breast cancer, pancreatic cancer, or bladder cancer) underwent whole-body (WB) PET/CT scans at 10, 40, and 180 min after the injection of [⁶⁸Ga]Ga-FZ-NR-1. The images were reconstructed using the Ordered Subset Expectation Maximization (OSEM) algorithm with TOF and PSF technology. The brain, salivary, heart, lungs, stomach, spleen, liver, gallbladder, pancreas, kidneys, colon, and prostate in males or uterus in females as target organs were semi-automatically segmented on PET/CT images using the Hermes Internal Radiation Dosimetry (HIRD) software toolkit. Time-activity curves (TACs) were obtained for these organs based on measured activity concentrations. The time-integrated activity coefficients (TIACs) of these target organs were calculated by integrating the TACs. Organ-specific absorbed doses and the total body effective dose were estimated using IDAC-Dose 2.1 software. Meanwhile, bladder dosimetry employed a standard voiding model.
results[⁶⁸Ga]Ga-FZ-NR-1 was cleared rapidly, primarily via the urinary system. The highest organ absorbed doses per injected activity unit were observed in the kidneys (2.24 × 10⁻¹ mGy/MBq) and bladder wall (1.24 × 10⁻¹ mGy/MBq). Other notable organs were the salivary glands, with an absorbed dose of approximately 2.54 × 10⁻² mGy/MBq. The estimated total body effective dose per injected activity unit was approximately 2.00 × 10⁻² mSv/MBq. Preliminary clinical imaging showed high tracer uptake in breast, pancreatic, and bladder cancer lesions, highlighting its promising diagnostic potential for detecting Nectin-4-expressing tumors.
conclusionThis human dosimetry assessment of [⁶⁸Ga]Ga-FZ-NR-1 showed a total body effective dose of approximately 2.00 × 10⁻² mSv/MBq, similar to other
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.